SK Bioscience Licenses CDC Rotavirus Tech, Aims for Global Vaccine Market Expansion — SK bioscience Co., Ltd.

Event summary

SK Bioscience licensed injectable rotavirus vaccine technology from the CDC in June 2026, becoming the first Korean company to do so.
The project is supported by a June 2025 funding agreement with the RIGHT Foundation, a public-private partnership backed by the Korean government, Gates Foundation, and Korean life science companies.
Rotavirus causes severe diarrhea in children under five, with 99% of global deaths occurring in low- and middle-income countries due to lower vaccine effectiveness in these regions.
The global rotavirus vaccine market is projected to grow from $8.12 billion in 2024 to $13.9 billion by 2033, with increasing demand from Gavi-supported countries.
SK Bioscience plans to enhance vaccine efficacy, reduce costs, and advance through clinical trials and commercialization.

The big picture

SK Bioscience's move to license CDC's rotavirus vaccine technology positions it to address a critical global health need, particularly in regions where oral vaccines have proven less effective. The partnership with the RIGHT Foundation underscores the growing trend of public-private collaborations in vaccine development, aiming to reduce the infectious disease burden in low- and middle-income countries. The projected growth of the rotavirus vaccine market highlights the strategic importance of this initiative for SK Bioscience's expansion in the global biotech sector.

What we're watching

Clinical Development: The pace at which SK Bioscience advances the vaccine through clinical trials and regulatory approval will determine its market entry timeline.
Market Penetration: Whether SK Bioscience can effectively compete in the growing rotavirus vaccine market, particularly in low- and middle-income countries.
Partnership Dynamics: How the collaboration with the RIGHT Foundation and CDC will influence the vaccine's development and commercialization strategy.